Genetic Technologies (Australia) Buy Hold or Sell Recommendation
| GTG Stock | 0.04 0.00 0.00% |
Assuming the 90 days trading horizon and your typical level of risk aversion, our recommendation regarding Genetic Technologies is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Genetic Technologies given historical horizon and risk tolerance towards Genetic Technologies. When Macroaxis issues a 'buy' or 'sell' recommendation for Genetic Technologies, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Genetic Technologies Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Genetic Stock please use our How to Invest in Genetic Technologies guide. Note, we conduct extensive research on individual companies such as Genetic and provide practical buy, sell, or hold advice based on investors' constraints. Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Genetic |
Execute Genetic Technologies Buy or Sell Advice
The Genetic recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Genetic Technologies. Macroaxis does not own or have any residual interests in Genetic Technologies or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Genetic Technologies' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Genetic Technologies Trading Alerts and Improvement Suggestions
| Genetic Technologies has some characteristics of a very speculative penny stock | |
| Genetic Technologies had very high historical volatility over the last 90 days | |
| Genetic Technologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 7.66 M. Net Loss for the year was (12.02 M) with profit before overhead, payroll, taxes, and interest of 6.01 M. | |
| Genetic Technologies generates negative cash flow from operations | |
| Latest headline from news.google.com: Genetic Technologies Enters Voluntary Administration - TipRanks |
Genetic Technologies Returns Distribution Density
The distribution of Genetic Technologies' historical returns is an attempt to chart the uncertainty of Genetic Technologies' future price movements. The chart of the probability distribution of Genetic Technologies daily returns describes the distribution of returns around its average expected value. We use Genetic Technologies price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Genetic Technologies returns is essential to provide solid investment advice for Genetic Technologies.
| Mean Return | 0.01 | Value At Risk | -7.14 | Potential Upside | 8.33 | Standard Deviation | 4.90 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Genetic Technologies historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Genetic Technologies Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (59.5K) | 14.5K | (351.4K) | 72.3K | 119.4K | 125.4K | |
| Change In Cash | 12.1M | 6.7M | 21.4M | (3.9M) | (6.8M) | (6.5M) | |
| Free Cash Flow | (5.8M) | (6.9M) | (5.8M) | (9.7M) | (9.7M) | (9.2M) | |
| Depreciation | 265.9K | 478.2K | 578.7K | 676.6K | 534.9K | 508.1K | |
| Other Non Cash Items | 316.7K | 303.5K | 892.9K | 1.4M | 1.4M | 1.5M | |
| Capital Expenditures | 38.1K | 642K | 96.8K | 17.6K | 33.0K | 31.3K | |
| Net Income | (6.3M) | (7.1M) | (7.1M) | (11.8M) | (12.0M) | (11.4M) | |
| End Period Cash Flow | 14.2M | 20.9M | 11.7M | 7.9M | 1.0M | 969.6K | |
| Change To Netincome | (606.5K) | 732.8K | 766.1K | 1.7M | 2.0M | 2.1M |
Genetic Technologies Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Genetic Technologies or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Genetic Technologies' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Genetic stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 4.27 | |
Ir | Information ratio | -0.02 |
Genetic Technologies Volatility Alert
Genetic Technologies exhibits above-average semi-deviation for your current time horizon. Genetic Technologies is a penny stock. Although Genetic Technologies may be in fact a good investment, many penny stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Genetic Technologies. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Genetic instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Genetic Technologies Fundamentals Vs Peers
Comparing Genetic Technologies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Genetic Technologies' direct or indirect competition across all of the common fundamentals between Genetic Technologies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Genetic Technologies or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Genetic Technologies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Genetic Technologies by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Genetic Technologies to competition |
| Fundamentals | Genetic Technologies | Peer Average |
| Return On Equity | -1.85 | -0.31 |
| Return On Asset | -0.63 | -0.14 |
| Profit Margin | (1.24) % | (1.27) % |
| Operating Margin | (1.13) % | (5.51) % |
| Current Valuation | 5.53 M | 16.62 B |
| Shares Outstanding | 145.42 M | 571.82 M |
| Shares Owned By Insiders | 5.56 % | 10.09 % |
| Price To Book | 3.10 X | 9.51 X |
| Price To Sales | 0.59 X | 11.42 X |
| Revenue | 7.66 M | 9.43 B |
| Gross Profit | 6.01 M | 27.38 B |
| EBITDA | (11.43 M) | 3.9 B |
| Net Income | (12.02 M) | 570.98 M |
| Total Debt | 875.19 K | 5.32 B |
| Book Value Per Share | 0.01 X | 1.93 K |
| Cash Flow From Operations | (9.68 M) | 971.22 M |
| Target Price | 0.25 | |
| Number Of Employees | 55 | 18.84 K |
| Beta | 0.48 | -0.15 |
| Market Capitalization | 5.67 M | 19.03 B |
| Total Asset | 6.19 M | 29.47 B |
| Retained Earnings | (166.38 M) | 9.33 B |
| Working Capital | (500.09 K) | 1.48 B |
| Net Asset | 6.19 M |
Genetic Technologies Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Genetic . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Genetic Technologies Buy or Sell Advice
When is the right time to buy or sell Genetic Technologies? Buying financial instruments such as Genetic Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Genetic Technologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Thematic Idea Now
Communication
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Communication theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.